<DOC>
	<DOC>NCT02194881</DOC>
	<brief_summary>The purpose of this study is to determine whether the treatment with Ivacaftor remains effective and safe in the patients with cystic fibrosis (and at least one G551D CFTR mutation) in the real life setting, after the drug has been approved by the Health authorities.</brief_summary>
	<brief_title>Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation</brief_title>
	<detailed_description>The aims of our study are: 1. to describe the treated population at initiation of treatment, 2. to evaluate clinical parameters during the year before Ivacaftor was started, at initiation of treatment and during at least one year of treatment, until June 2014. 3. to evaluate the tolerance and safety of this treatment.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>French patients with CF aged 6 or older who are homozygous or heterozygous for the G551D mutation Treated with Ivacaftor First prescription of Ivacaftor before June 1st 2013 (including patients randomized in the VX770 clinical trials) CF patients younger than 6 years old CF patients who have received lung transplantation CF patients without a G551D mutation.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>G551D mutation</keyword>
	<keyword>Novel treatments</keyword>
	<keyword>Potentiator</keyword>
	<keyword>Ivacaftor</keyword>
</DOC>